Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus's ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

Indeed, a recent study published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology found a prolonged ...

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...

The following is a summary of “Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and ...

New findings from the National Institutes of Health’s (NIH) Researching COVID to Enhance Recovery (RECOVER(link is external)) ...

A study in Ecuador reveals the rapid emergence of SARS-CoV-2 variants, highlighting the importance of strengthening genomic ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...